A common vitamin may treat damaged lungs when inhaled.
A common vitamin may treat damaged lungs when inhaled.
Swallowing vitamin D pills has failed to help patients with chronic lung diseases — but a groundbreaking new approach suggests inhaling the vitamin directly into the lungs could bypass the body's natural barriers and finally deliver relief.
For years, clinical
trials testing oral vitamin D supplements in patients with chronic obstructive
pulmonary disease (COPD), asthma, and cystic fibrosis have consistently failed
to show meaningful improvements in lung function or quality of life. Now, researchers at the University of North
Carolina School of Medicine and the COPD Foundation believe they have
discovered why.
When vitamin D is
swallowed, it enters the bloodstream and makes its way to the lungs. There, an
enzyme in the blood vessels of the lungs likely deactivates the vitamin before
it can reach the tissues of the airways that require it the most. This
enzymatic barrier explains why simply raising vitamin D levels in the blood
does not translate to better respiratory health.
To overcome this
obstacle, scientists are proposing a shift toward delivering vitamin D directly
into the airways via inhalation or nebulization. While preclinical animal and cellular models
indicate that inhaled vitamin D can protect airway linings, reduce
inflammation, and defend against environmental pathogens, researchers emphasize
that human trials are still needed to establish safety and proper dosing.
With over 30 million
Americans currently living with COPD, this innovative and targeted respiratory
strategy could ultimately revolutionize how we protect damaged lungs.
source: Schichlein,
K. D., & Jaspers, I. (2026).
The case for targeted respiratory delivery when considering vitamin D
supplementation in pulmonary disease. Chronic Obstructive Pulmonary Diseases:
Journal of the COPD Foundation.
Comments
Post a Comment